Article Figures & Data
- Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 flow diagram for new systematic reviews which included searches of databases and registers only. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.
- Figure 2
Mechanism of different medications inhibiting the neointimal hyperplasia.
- Table 1
Summary of basic characteristics and outcomes
Characteristics Value Cohort size (n) 1928 Demographics Age (years), mean (SD) (n=1889) 63.4±NA Gender (male) (n=1889) 1490 (78.87%) Risk factors Hypertension (n=1657) 1332 (80.39%) Diabetes mellitus (n=1657) 579 (34.94%) Coronary artery disease (n=706) 162 (22.95%) Dyslipidaemia (n=1375) 742 (53.96%) Tobacco smoking (n=1630) 811 (49.75%) Outcome Mean time from onset symptom to recanalisation day (n=1139) 21.188±NA Procedure stroke/TIA rates (n=64) 9 (14.06%) Periprocedural stroke rate and death from any cause (within 30 days of treatment) (n=891) 63 (7.07%) Mean follow-up (months) (n=1928) 18.96±NA Rate of stroke/TIA during clinical follow-up period (n=1398) 108 (7.73%) Rate of restenosis (>50%) during follow-up (n=1059) 102 (9.63%) Mortality (n=1090) 51 (4.68%) Studies quality (n=31) Good 16 (51.61%) Fair 13 (41.93%) Poor 2 (6.45%) NA, not applicable; TIA, transient ischaemic attack.
Supplementary Materials
Supplementary data
Additional Files
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
